




**OSI 10-K Filed
Dec. 28, 1998**

**Gibbs Published
Jan. 1, 2000**

**Priority Application Describing
Method of Treatment of NSCLC
with Erlotinib – Mar. 30, 2000**

**Tarceva Approved for
NSCLC Indication
Nov. 18, 2004**

**Schnur issues
as U.S. Patent
May 5, 1998**



**First Patient Dosed in
Phase II NSCLC Trial
Jan. 25, 2000**



**Efficacy Studies for Erlotinib
in NSCLC Reported
2002 – 2004***



* Ex. 2004 at 2004-0012-2004-0013; Ex. 2019 n. 29, 35-38, 41; 2020, Giaccone Dep. 139:20-144:13, 156:10-161:21